Form 4: Pacific Biosciences Director Hannah Valantine Reports Acquisition of Stock Options and Restricted Stock Units
SEC Form 4 Filing
Director Hannah Valantine reported the acquisition of stock options and restricted stock units in Pacific Biosciences of California, Inc.
Summary
- On June 18, 2024, Hannah Valantine, a director at Pacific Biosciences of California, Inc. (PACB), reported the acquisition of 22,821 Restricted Stock Units (RSUs) and stock options for 32,179 shares.
- The RSUs vest on the one-year anniversary of the grant date or the next annual meeting, provided Valantine continues to serve as a director.
- The stock options, with an exercise price of $1.65, vest monthly over one year, also contingent on continued service as a director.
- Following these transactions, Valantine directly owns 22,821 shares represented by RSUs and holds options for 32,179 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of shares and options can be seen as a positive sign, but it's not necessarily indicative of a major shift in the company's prospects.
Positives
- The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.
- The vesting schedules tied to continued service as a director align the director's interests with those of the shareholders.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.
Key Dates
| Date | Description |
|---|---|
| 06/18/2024 | Date of the transaction: acquisition of RSUs and stock options. |
| 07/18/2024 | The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
| 06/18/2034 | Expiration date of the stock options. |
| 06/20/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.